"label","studyEstimands","documentVersion","uuid:ID","description","studyDesignRationale","id","bcCategories","studyInvestigationalInterventions","name"
"","[]","","228d11cf-61ef-4e6c-aba4-bcb7b4aa2b46","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","[]","[]","Study Design 1"
